Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

2.

PheProb: probabilistic phenotyping using diagnosis codes to improve power for genetic association studies.

Sinnott JA, Cai F, Yu S, Hejblum BP, Hong C, Kohane IS, Liao KP.

J Am Med Inform Assoc. 2018 Oct 1;25(10):1359-1365. doi: 10.1093/jamia/ocy056.

3.

Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency.

Sinnott JA, Brumberg K, Wilson KM, Ebot EM, Giovannucci EL, Mucci LA, Rider JR.

Eur Urol. 2018 Nov;74(5):545-548. doi: 10.1016/j.eururo.2018.05.006. Epub 2018 May 18.

4.

Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.

Felix AS, Sinnott JA, Vetter MH, Rhoades J, Cohn DE, Backes FJ, Sherman ME, Suarez AA.

Gynecol Oncol. 2018 Jul;150(1):38-43. doi: 10.1016/j.ygyno.2018.05.005. Epub 2018 May 10.

5.

Pathway aggregation for survival prediction via multiple kernel learning.

Sinnott JA, Cai T.

Stat Med. 2018 Jul 20;37(16):2501-2515. doi: 10.1002/sim.7681. Epub 2018 Apr 17.

6.

Life after endometrial cancer: A systematic review of patient-reported outcomes.

Shisler R, Sinnott JA, Wang V, Hebert C, Salani R, Felix AS.

Gynecol Oncol. 2018 Feb;148(2):403-413. doi: 10.1016/j.ygyno.2017.11.007. Epub 2017 Nov 14. Review.

PMID:
29150143
7.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

8.

The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

9.

Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL.

Clin Cancer Res. 2017 Jan 1;23(1):81-87. doi: 10.1158/1078-0432.CCR-16-1245. Epub 2016 Sep 23.

10.

Cholesterol Metabolism and Prostate Cancer Lethality.

Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR.

Cancer Res. 2016 Aug 15;76(16):4785-90. doi: 10.1158/0008-5472.CAN-16-0903. Epub 2016 Jun 20.

11.

Kernel machine score test for pathway analysis in the presence of semi-competing risks.

Neykov M, Hejblum BP, Sinnott JA.

Stat Methods Med Res. 2018 Apr;27(4):1099-1114. doi: 10.1177/0962280216653427. Epub 2016 Jun 2.

13.

Inference for survival prediction under the regularized Cox model.

Sinnott JA, Cai T.

Biostatistics. 2016 Oct;17(4):692-707. doi: 10.1093/biostatistics/kxw016. Epub 2016 Apr 22.

14.

Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.

Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL.

Eur Urol. 2016 Dec;70(6):974-982. doi: 10.1016/j.eururo.2016.03.027. Epub 2016 Mar 28.

15.

Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.

Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K.

Clin Cancer Res. 2016 Feb 1;22(3):765-772. doi: 10.1158/1078-0432.CCR-15-0101. Epub 2015 Oct 21.

16.

Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.

Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M.

Mol Cancer Res. 2015 Oct;13(10):1431-40. doi: 10.1158/1541-7786.MCR-14-0569. Epub 2015 Jun 29.

17.

Molecular differences in transition zone and peripheral zone prostate tumors.

Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O.

Carcinogenesis. 2015 Jun;36(6):632-8. doi: 10.1093/carcin/bgv051. Epub 2015 Apr 13.

18.

Tumor expression of adiponectin receptor 2 and lethal prostate cancer.

Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2015 Jun;36(6):639-47. doi: 10.1093/carcin/bgv048. Epub 2015 Apr 11.

19.

Association of prostate cancer risk variants with gene expression in normal and tumor tissue.

Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-60. doi: 10.1158/1055-9965.EPI-14-0694-T. Epub 2014 Nov 4.

20.

Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records.

Sinnott JA, Dai W, Liao KP, Shaw SY, Ananthakrishnan AN, Gainer VS, Karlson EW, Churchill S, Szolovits P, Murphy S, Kohane I, Plenge R, Cai T.

Hum Genet. 2014 Nov;133(11):1369-82. doi: 10.1007/s00439-014-1466-9. Epub 2014 Jul 26.

21.

Omnibus risk assessment via accelerated failure time kernel machine modeling.

Sinnott JA, Cai T.

Biometrics. 2013 Dec;69(4):861-73. doi: 10.1111/biom.12098. Epub 2013 Nov 6.

22.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

23.

Gleason grade progression is uncommon.

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M.

Cancer Res. 2013 Aug 15;73(16):5163-8. doi: 10.1158/0008-5472.CAN-13-0427.

24.

Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ.

Carcinogenesis. 2012 Feb;33(2):404-12. doi: 10.1093/carcin/bgr290. Epub 2011 Dec 8.

25.

Artifact due to differential error when cases and controls are imputed from different platforms.

Sinnott JA, Kraft P.

Hum Genet. 2012 Jan;131(1):111-9. doi: 10.1007/s00439-011-1054-1. Epub 2011 Jul 7.

26.

mRNA expression signature of Gleason grade predicts lethal prostate cancer.

Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA.

J Clin Oncol. 2011 Jun 10;29(17):2391-6. doi: 10.1200/JCO.2010.32.6421. Epub 2011 May 2.

27.

Genome-wide association study of prostate cancer mortality.

Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76. doi: 10.1158/1055-9965.EPI-10-0601. Epub 2010 Oct 26.

28.

Endoscopist-directed administration of propofol: a worldwide safety experience.

Rex DK, Deenadayalu VP, Eid E, Imperiale TF, Walker JA, Sandhu K, Clarke AC, Hillman LC, Horiuchi A, Cohen LB, Heuss LT, Peter S, Beglinger C, Sinnott JA, Welton T, Rofail M, Subei I, Sleven R, Jordan P, Goff J, Gerstenberger PD, Munnings H, Tagle M, Sipe BW, Wehrmann T, Di Palma JA, Occhipinti KE, Barbi E, Riphaus A, Amann ST, Tohda G, McClellan T, Thueson C, Morse J, Meah N.

Gastroenterology. 2009 Oct;137(4):1229-37; quiz 1518-9. doi: 10.1053/j.gastro.2009.06.042. Epub 2009 Jun 21. Review.

PMID:
19549528
29.

Toll-like receptor signaling pathway variants and prostate cancer mortality.

Stark JR, Wiklund F, Grönberg H, Schumacher F, Sinnott JA, Stampfer MJ, Mucci LA, Kraft P.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1859-63. doi: 10.1158/1055-9965.EPI-08-0981.

30.

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA.

J Clin Oncol. 2009 Jul 20;27(21):3459-64. doi: 10.1200/JCO.2008.20.4669. Epub 2009 May 11.

31.

Unusual complication of naso-enteric feeding tube.

Sinnott JA, Levinson J.

Gastrointest Endosc. 1991 Sep-Oct;37(5):584-5. No abstract available.

PMID:
1936850

Supplemental Content

Loading ...
Support Center